After a financial maneuver by Legend Biotech, GenScript Biotech no longer considers itself the cell therapy biotech’s majority shareholder. (pengtianli/iStock/Getty ...
Legend Biotech Corp. LEGN stock fell in Thursday’s premarket trading after the cell therapy company priced an underwritten public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 ...
Analysts' ratings for Legend Biotech (NASDAQ:LEGN) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The following table encapsulates their recent ratings, offering a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results